Starling Oncology, Inc.

STLN Nasdaq SEC CIK 1799191
Follow Starling Oncology Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $169.8M +24.3% vs same quarter last year
Net income −$15.7M +4.6% vs same quarter last year
EPS, diluted −$0.13 +7.1% vs same quarter last year
Operating cash flow $10.1M +180.3% vs same quarter last year
Revenue by quarter
$100.3M
$104.4M
$119.8M
$136.6M
$142M
$147.4M
$161.3M
$169.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$200M$0$200M$400M$600MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$502.7M-
FY24$393.4M-
FY23$324.2M−$83.1M
FY22$252.5M$152K
FY21$203M−$10.9M
FY20$187.5M−$14.3M
FY19--
MarginsShare of revenue
  • Operating margin
  • Net margin
−40%−30%−20%−10%0%10%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−7.2%-
FY24−15.3%-
FY23−23.8%−25.6%
FY22−32.5%0.1%
FY21−22.6%−5.4%
FY20−4.4%−7.6%
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$27.8M
FY24−$30.3M
FY23−$40.9M
FY22−$67.3M
FY21−$35.5M
FY20−$686K
FY19-
Returned to shareholdersDividends paid and shares bought back
$0$2.5M$5M$7.5M$10MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBuybacks
FY25-
FY24$0
FY23$1M
FY22$9M
FY21$0
FY20-
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Starling Oncology
  • Healthcare median
−100%−75%−50%−25%0%25%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearStarling OncologyHealthcare median
FY25-−30.6%
FY24-−47%
FY23−25.6%−58%
FY220.1%−80.4%
FY21−5.4%−71.9%
FY20−7.6%−62.2%
FY19-−46.3%